scholarly journals Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Arash Atrsaei ◽  
Marta Francisca Corrà ◽  
Farzin Dadashi ◽  
Nuno Vila-Chã ◽  
Luis Maia ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Functional Capacity ◽  
Gait Speed ◽  
Real Life ◽  
Gaussian Model ◽  
Daily Activities ◽  
Actual Performance ◽  
Life Conditions ◽  
Medication Intake

AbstractGait speed often referred as the sixth vital sign is the most powerful biomarker of mobility. While a clinical setting allows the estimation of gait speed under controlled conditions that present functional capacity, gait speed in real-life conditions provides the actual performance of the patient. The goal of this study was to investigate objectively under what conditions during daily activities, patients perform as well as or better than in the clinic. To this end, we recruited 27 Parkinson’s disease (PD) patients and measured their gait speed by inertial measurement units through several walking tests in the clinic as well as their daily activities at home. By fitting a bimodal Gaussian model to their gait speed distribution, we found that on average, patients had similar modes in the clinic and during daily activities. Furthermore, we observed that the number of medication doses taken throughout the day had a moderate correlation with the difference between clinic and home. Performing a cycle-by-cycle analysis on gait speed during the home assessment, overall only about 3% of the strides had equal or greater gait speeds than the patients’ capacity in the clinic. These strides were during long walking bouts (>1 min) and happened before noon, around 26 min after medication intake, reaching their maximum occurrence probability 3 h after Levodopa intake. These results open the possibility of better control of medication intake in PD by considering both functional capacity and continuous monitoring of gait speed during real-life conditions.

scholarly journals Virtual Reality Functional Capacity Assessment Tool (VRFCAT-SL) in Parkinson’s Disease

2021 ◽  
pp. 1-9
Author(s):  
Travis H. Turner ◽  
Alexandra Atkins ◽  
Richard S.E. Keefe
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Virtual Reality ◽  
Cognitive Impairment ◽  
Functional Capacity ◽  
Visual Memory ◽  
Assessment Tool ◽  
Task Force ◽  
Self Report ◽  
Capacity Assessment

Background: Cognitive impairment is common in Parkinson’s disease (PD) and highly associated with loss of independence, caregiver burden, and assisted living placement. The need for cognitive functional capacity tools validated for use in PD clinical and research applications has thus been emphasized in the literature. The Virtual Reality Functional Capacity Assessment Tool (VRFCAT-SL) is a tablet-based instrument that assesses proficiency for performing real world tasks in a highly realistic environment. Objective: The present study explored application of the VRFCAT-SL in clinical assessments of patients with PD. Specifically, we examined associations between VRFCAT-SL performance and measures of cognition, motor severity, and self-reported cognitive functioning. Methods: The VRFCAT-SL was completed by a sample of 29 PD patients seen in clinic for a comprehensive neuropsychological evaluation. Fifteen patients met Movement Disorders Society Task Force criteria for mild cognitive impairment (PD-MCI); no patients were diagnosed with dementia. Non-parametric correlations between VRFCAT-SL performance and standardized neuropsychological tests and clinical measures were examined. Results: VRFCAT-SL performance was moderately associated with global rank on neuropsychological testing and discriminated PD-MCI. Follow-up analyses found completion time was associated with visual memory, sustained attention, and set-switching, while errors were associated with psychomotor inhibition. No clinical or motor measures were associated with VRFCAT-SL performance. Self-report was not associated with VRFCAT-SL or neuropsychological test performance. Conclusion: The VRFCAT-SL appears to provide a useful measure of cognitive functional capacity that is not confounded by PD motor symptoms. Future studies will examine utility in PD dementia.

The effects of levodopa in the spatiotemporal gait parameters are mediated by self‐selected gait speed in Parkinson’s disease

2021 ◽  
Author(s):  
Júlia Ávila de Oliveira ◽  
Paulo Rodrigo Bazán ◽  
Claudia Eunice Neves Oliveira ◽  
Renata Castro Treza ◽  
Sandy Mikie Hondo ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Gait Speed ◽  
Gait Parameters

Real life evaluation of safinamide effectiveness in Parkinson’s disease

2018 ◽  
Vol 39 (4) ◽  
pp. 733-739 ◽  
Author(s):  
Francesca Mancini ◽  
Alessio Di Fonzo ◽  
Giulia Lazzeri ◽  
Linda Borellini ◽  
Vincenzo Silani ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Real Life ◽  
Life Evaluation

Comprehensive analysis of resting tremor based on acceleration signals of patients with Parkinson’s disease

2021 ◽  
pp. 1-13
Author(s):  
Sen Liu ◽  
Han Yuan ◽  
Jiali Liu ◽  
Hai Lin ◽  
Cuiwei Yang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Statistical Tests ◽  
Real Life ◽  
Feature Analysis ◽  
Support Vector ◽  
Monitoring Methods ◽  
Resting Tremor ◽  
Acceleration Signals

BACKGROUND: Resting tremor is an essential characteristic in patients suffering from Parkinson’s disease (PD). OBJECTIVE: Quantification and monitoring of tremor severity is clinically important to help achieve medication or rehabilitation guidance in daily monitoring. METHODS: Wrist-worn tri-axial accelerometers were utilized to record the long-term acceleration signals of PD patients with different tremor severities rated by Unified Parkinson’s Disease Rating Scale (UPDRS). Based on the extracted features, three kinds of classifiers were used to identify different tremor severities. Statistical tests were further designed for the feature analysis. RESULTS: The support vector machine (SVM) achieved the best performance with an overall accuracy of 94.84%. Additional feature analysis indicated the validity of the proposed feature combination and revealed the importance of different features in differentiating tremor severities. CONCLUSION: The present work obtains a high-accuracy classification in tremor severity, which is expected to play a crucial role in PD treatment and symptom monitoring in real life.

Trends and New Advances on Wearable and Mobile Technologies for Parkinson's Disease Monitoring and Assessment of Motor Symptoms

2018 ◽  
pp. 1388-1412
Author(s):  
Jorge Cancela ◽  
Matteo Pastorino ◽  
Maria Teresa Arredondo Waldmeyer
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Full Range ◽  
Mobile Technologies ◽  
Daily Activities ◽  
Disease Monitoring ◽  
Motor Symptoms ◽  
Different Dimensions

The aim of this work is to analyze the trends and new advances carried out in the last decades in the field of Parkinson's disease monitoring and management and more specifically regarding wearable and mobile technologies. The challenges of such technologies is to monitor, to assess and to manage the full range of PD symptoms through monitoring and testing routines while not hampering the patient's daily activities, identifying the correlation between the different dimensions affecting the severity of symptoms and the evolution of the disease and enabling the clinician to manage more efficiently the patient by providing timely indications on the effectiveness of the therapy and suggestions on therapy changes.

scholarly journals Versatile guideline-based physiotherapy intervention in groups to improve gait speed in Parkinson’s disease patients

2019 ◽  
Vol 44 (4) ◽  
pp. 579-586 ◽  
Author(s):  
Kadri Medijainen ◽  
Mati Pääsuke ◽  
Aet Lukmann ◽  
Pille Taba
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Gait Speed ◽  
Physiotherapy Intervention

A Real-Life Search for the Optimal Set of Conversion Factors to Levodopa-Equivalent-Dose in Parkinson’s Disease Patients on Polytherapy

2020 ◽  
Vol 10 (1) ◽  
pp. 173-178
Author(s):  
Muneer Abu Snineh ◽  
Amal Hajyahya ◽  
Eduard Linetsky ◽  
Renana Eitan ◽  
Hagai Bergman ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Real Life ◽  
Equivalent Dose ◽  
Conversion Factors ◽  
Optimal Set

▼ Safinamide for Parkinson’s disease

2018 ◽  
Vol 56 (5) ◽  
pp. 54-57
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Motor Fluctuations ◽  
Daily Activities ◽  
Monoamine Oxidase B ◽  
Motor Symptoms ◽  
Idiopathic Parkinson’S Disease ◽  
Mao B ◽  
Idiopathic Parkinson's Disease

▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson’s disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson’s disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor.

scholarly journals REM Sleep Behavior Disorder in Parkinson’s Disease: Effects on Cognitive, Psychiatric, and Functional outcomes

2020 ◽  
Vol 26 (9) ◽  
pp. 894-905
Author(s):  
Zanjbeel Mahmood ◽  
Ryan Van Patten ◽  
Marina Z. Nakhla ◽  
Elizabeth W. Twamley ◽  
J. Vincent Filoteo ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Functional Capacity ◽  
Psychiatric Symptoms ◽  
Neuropsychological Functioning ◽  
Visual Learning ◽  
Rem Sleep Behavior Disorder ◽  
Behavior Disorder ◽  
Learning Performance ◽  
Sleep Behavior

AbstractObjective:Rapid eye movement sleep behavior disorder (RBD) affects 33–46% of patients with Parkinson’s disease (PD) and may be a risk factor for neuropsychological and functional deficits. However, the role of RBD on neuropsychological functioning in PD has yet to be fully determined. We, therefore, examined differences in neurocognitive performance, functional capacity, and psychiatric symptoms among nondemented PD patients with probable RBD (PD/pRBD+) and without (PD/pRBD−), and healthy comparison participants (HC).Methods:Totally, 172 participants (58 PD/pRBD+; 65 PD/pRBD−; 49 HC) completed an RBD sleep questionnaire, psychiatric/clinical questionnaires, performance-based and self-reported functional capacity measures, and underwent a comprehensive neuropsychological battery assessing attention/working memory, language, visuospatial function, verbal and visual learning and memory, and executive function.Results:Controlling for psychiatric symptom severity, the PD/pRBD+ group had poorer executive functioning and learning performance than the PD/pRBD− group and poorer neuropsychological functioning across all individual cognitive domains than the HCs. In contrast, PD/pRBD− patients had significantly lower scores than HCs only in the language domain. Moreover, PD/pRBD+ patients demonstrated significantly poorer medication management skills compared to HCs. Both PD groups reported greater depressive and anxiety severity compared to HCs; PD/pRBD+ group also endorsed greater severity of apathy compared to HCs.Conclusions:The presence of pRBD is associated with poorer neuropsychological functioning in PD such that PD patients with pRBD have poorer cognitive, functional, and emotional outcomes compared to HC participants and/or PD patients without pRBD. Our findings underscore the importance of RBD assessment for improved detection and treatment of neuropsychological deficits (e.g., targeted cognitive interventions).

Sign in / Sign up

Export Citation Format

Share Document